Latest 10-K annual reports

a.k.a. Brands Holding Corp. reported a 4% increase in net sales to $600.2 million for fiscal year 2025, driven by a 6% rise in orders, despite an increase in net loss and a decrease in Adjusted EBITDA.

BCP Investment Corporation reports a net increase in assets from operations for 2025, driven by strategic acquisitions and portfolio activity, despite a decline in net asset value per share.

EyePoint, Inc. reports a net loss of $232.0 million for fiscal year 2025, driven by increased R&D for its lead candidate DURAVYU, which is progressing in Phase 3 trials for wet AMD and DME.

Amalgamated Financial Corp. reported a slight dip in net income and EPS for 2025, despite growth in assets and deposits, alongside increased credit loss provisions and non-interest expenses.

Mobile Infrastructure Corporation reported a net loss of $22.4 million for 2025, driven by increased interest expenses and asset impairments, while actively managing debt maturities and optimizing its parking portfolio.

Olaplex Holdings, Inc. reported a net loss of $9.3 million for fiscal year 2025, despite a slight increase in total net sales and strategic investments in innovation and debt reduction.

Research Frontiers Incorporated reported a net loss of $2.0 million for fiscal year 2025, a significant increase from the prior year, primarily due to decreased fee income and higher operating expenses, despite strategic advancements in SPD-SmartGlass technology.

Intrepid Potash, Inc. reported a significant turnaround in 2025 with $11.2 million net income, driven by increased Trio sales and strategic initiatives, despite challenges in water sales.

L.B. Foster Company reported a 1.7% increase in net sales to $540.0 million in 2025, driven by Infrastructure growth, but net income significantly declined due to tax adjustments and restructuring costs.

Solitario Resources Corp. reported a reduced net loss in 2025, driven by lower exploration and administrative expenses, while advancing its core mineral exploration projects and securing new capital.

Park-Ohio Holdings Corp. reported a significant 41% decrease in income from continuing operations for 2025, driven by lower customer demand across all segments and asset impairment charges.

Uwharrie Capital Corp announced a significant increase in net income and asset growth for fiscal year 2025, driven by robust mortgage banking and loan portfolio expansion.

Carter Bankshares, Inc. announced a significant increase in net income and diluted earnings per share for 2025, driven by loan growth and improved net interest margin.

Global Crossing Airlines Group Inc. reported its first positive operating income in 2025, driven by strong ACMI demand and strategic fleet growth, despite ongoing net losses and liquidity concerns.

OFG Bancorp filed an Amendment No. 1 to its 2025 Annual Report on Form 10-K to correct an incorrect check box regarding its well-known seasoned issuer status.

National Research Corporation (NRC Health) reported a decrease in 2025 revenue and operating income but anticipates growth in 2026 driven by record Total Recurring Contract Value and strategic initiatives.

Ranpak Holdings Corp. reported a 7.1% increase in net revenue to $395.0 million for 2025, driven by void-fill and automation sales, but experienced a significant rise in net loss and a decrease in EBITDA.

Rand Capital Corporation's 2025 annual report reveals a substantial decrease in total assets and net asset value per share, alongside a shift to net realized investment losses and increased unrealized depreciation.

CorMedix Inc. reported significant revenue growth and net income in 2025, driven by the successful commercialization of DefenCath and the strategic acquisition of Melinta Therapeutics, despite facing future reimbursement challenges.

Acorn Energy, Inc. reported a 5% increase in 2025 revenue driven by strong monitoring services growth and new product launches, alongside a strategic partnership for North American IoT expansion.

Aligos Therapeutics reports continued pipeline advancement in HBV, MASH, and coronavirus programs, alongside significant net losses and substantial doubt about its ability to continue as a going concern.

flyExclusive reported a significantly reduced net loss in 2025, driven by strong revenue growth in fractional ownership and MRO services, despite ongoing legal challenges and internal control weaknesses.

Okta, Inc. reported a significant turnaround to net income in fiscal year 2026, driven by subscription revenue growth and strategic investments in AI identity solutions.

Silence Therapeutics reported a significant net loss of $88.6 million for 2025, alongside AstraZeneca's decision to discontinue further development of SLN312 beyond Phase 1.

Distribution Solutions Group, Inc. (DSG) reported a return to net income and significant revenue growth for the fiscal year ended December 31, 2025, driven by strategic acquisitions and organic expansion.

Bioventus Inc. reported a significant return to net income and increased Adjusted EBITDA in 2025, driven by strategic divestitures and new product launches, despite a slight dip in overall net sales.

Kura Oncology achieved a pivotal milestone with FDA approval and commercial launch of KOMZIFTI for relapsed or refractory NPM1-mutated AML, while advancing a diversified oncology pipeline.

Compass Therapeutics, Inc. announced positive Phase 2/3 trial results for tovecimig in biliary tract cancer, alongside pipeline advancements and new executive hires, while reporting increased net losses for 2025.

Invivyd, Inc. reports increased PEMGARDA sales and significant clinical progress for VYD2311 in 2025, yet faces substantial doubt about its ability to continue as a going concern due to recurring losses.

Climb Bio, Inc. reported a net loss of $59.9 million for fiscal year 2025, while actively progressing its lead product candidates, budoprutug and CLYM116, through multiple clinical trials for immune-mediated diseases.